About us

An ocean of ideas

Marinomed at a glance

Marinomed Biotech AG is a biopharmaceutical company focused on inventing, developing, and partnering clinically meaningful therapies for patients suffering from serious viral infectious diseases and autoreactive immune disorders. Our business model is based on what we do best: validating innovative approaches, preclinical and clinical drug development, and out-licensing. In successful collaborations, we leverage what our pharmaceutical partners do best: clinical development, regulatory affairs and commercialization. Marinomed has received multiple prestigious research awards for its activities.

Since its foundation in 2006, Marinomed has launched two powerful technologies with great potential for treating viral diseases, and immune disorders. An active pipeline with both Carragelose®- and Marinosolv®-based candidates has successfully proven the value of these technologies in respiratory viral and allergy indications, respectively.

The Marinosolv® solubilization technology enhances the efficacy and bioavailability of hardly water-soluble compounds. This innovative technology has the potential to sustainably change a number of therapies for indications in the field of autoreactive immune disorders. The flagship product Budesolv (solubilized Budesonide) for the treatment of allergic rhinitis has successfully completed a pivotal Phase 3 clinical study and has been outlicensed to a first partner for the development and marketing in Greater China.

Marinomed also offers Solv4U technology partnerships based on its patented-protected Marinosolv® technology to support pharmaceutical companies in formulation development for hydrophobic small-moleculesin all stages of drug discovery.

The virology segment includes Carragelose® based over-the-counter products for the prophylaxis and therapy of viral infections of the upper respiratory tract, which are partnered in more than 40 countries with international partners. In addition, Marinomed is developing drugs based on iota-carrageenan for various serious viral infectious diseases.


Carragelose® effective against SARS-CoV-2 and first deal for Marinosolv®

Positive clinical data against SARS-CoV-2

Encouraging clinical data for Tacrosolv

First international deal for the Marinosolv platform with USD 2 million down payment

COVID, Marinosolv® patent & new headquarter in Korneuburg

Two clinical trials of Carragelose nasal sprays for the treatment and prevention of COVID-19 initiated after successful in vitro results against SARS-CoV-2

Marinosolv platform receives patent for the generation of aqueous solutions from insoluble compounds Implementation of new Marinomed headquarter in Korneuburg, AT

IPO & Validation of Marinosolv® technology

 IPO in February, quotation in the prime market segment at Vienna Stock Exchange

Clinical validation of the Marinosolv® platform with successful completion of phase III pivotal study for Budesolv

R&D advances

Certification of a new Carragelose® nasal spray with decongestant properties

Start of phase III clinical study for the flagship product Budesolv

Stock corporation & Budesolv flagship product

Change of legal form to a stock corporation

Preparation of a phase III clinical study for the flagship product Budesolv

Marinosolv® development

Development of and feasibility study for the Marinosolv® technology platform

Start: Carragelose®-business grows

Further product launches and sales partnerships

Carragelose®-business network established

Approval in 22 additional countries

Development of an independent sales network with outsourced production and logistics begins

Licensing partnership with Boehringer Ingelheim, initially for 54 countries

Market launch of the first Carragelose® product and equity investment by Acropora

Carragelose® development

Development of the virus-blocking compound Carragelose® derived from red seaweed


Foundation and start-up financing for Marinomed Biotechnologie GmbH as a spin-off from the University of Veterinary Medicine in Vienna